Pneumococcal immunity and PCV13 vaccine response in SOT-candidates and recipients
- PMID: 34023135
- DOI: 10.1016/j.vaccine.2021.05.030
Pneumococcal immunity and PCV13 vaccine response in SOT-candidates and recipients
Abstract
Background: Solid organ transplantation (SOT) candidates and recipients are highly vulnerable to invasive pneumococcal diseases (IPD). Data on which to base optimal immunization recommendations for this population is scant. The national distribution of IPD serotypes led the Swiss Health Authorities to recommend in 2014 one dose of pneumococcal-13-valent-conjugate-vaccine (PCV13), without any subsequent dose of the 23-valent-polysaccharide-pneumococcal-vaccine (PPV23).
Methods: This is a retrospective analysis of pneumococcal immunity using a multiplex binding assay, to assess seroprotection rates against a selection of seven PCV13- and seven PPV23-serotypes in SOT-candidates and recipients evaluated and/or transplanted in 2014/2015 in the University Hospitals of Geneva. Seroprotection was defined as serotype-specific antibody concentration greater than 0.5 mg/l and overall seroprotection when this was achieved for ≥ 6/7 serotypes.
Results: Pre-vaccination and at time of transplant sera were available for 35/43 (81%), and 43/43 (100%) SOT-candidates respectively. At listing, 17/35 (49%) SOT-candidates were seroprotected against PCV13 and 21/35 (60%) against PPV23 serotypes. Following one systematic dose of PCV13 at listing, 35/43 (81%) SOT-recipients were seroprotected at day of transplant against PCV13-serotypes and 34/43 (79%) against PPV23 serotypes, compared to 21/41 (51%) and 28/41 (68%) respectively in the controls transplanted in 2013, before the systematic PCV13-vaccination.
Conclusions: The systematic vaccination with PCV13 of all SOT candidates without additional PPV23 is a good strategy as it confers seroprotection against a wide range of pneumococcal serotypes. Indeed, one of five PCV13-vaccinated SOT-candidates was nevertheless not seroprotected at time of transplant, reflecting their partial immune competence, and indicating the need for additional dose of pneumococcal vaccines before transplant.
Keywords: Solid organ Transplantation; Vaccine.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
A randomized, controlled trial comparing the immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccination to a repeated dose 13-valent pneumococcal conjugate vaccination in adult liver transplant recipients.Vaccine. 2021 Apr 22;39(17):2351-2359. doi: 10.1016/j.vaccine.2021.03.063. Epub 2021 Mar 31. Vaccine. 2021. PMID: 33812743 Clinical Trial.
-
A randomized, controlled trial comparing the immunogenecity and safety of a 23-valent pneumococcal polysaccharide vaccination to a repeated dose 13-valent pneumococcal conjugate vaccination in kidney transplant recipients.Transpl Infect Dis. 2020 Aug;22(4):e13343. doi: 10.1111/tid.13343. Epub 2020 Jun 23. Transpl Infect Dis. 2020. PMID: 32473046 Clinical Trial.
-
Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.Vaccine. 2013 Dec 16;31(52):6232-8. doi: 10.1016/j.vaccine.2013.10.032. Epub 2013 Oct 29. Vaccine. 2013. PMID: 24176490
-
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis.Vaccine. 2019 Feb 14;37(8):1021-1029. doi: 10.1016/j.vaccine.2019.01.014. Epub 2019 Jan 23. Vaccine. 2019. PMID: 30685252
-
Pneumococcal Vaccination in Adults: What Can We Learn From Observational Studies That Evaluated PCV13 and PPV23 Effectiveness in the Same Population?Arch Bronconeumol. 2023 Mar;59(3):157-164. doi: 10.1016/j.arbres.2022.12.015. Epub 2023 Jan 7. Arch Bronconeumol. 2023. PMID: 36681604 Review. English, Spanish.
Cited by
-
Establishment of an ELISpot Assay to Detect Cellular Immunity against S. pneumoniae in Vaccinated Kidney Transplant Recipients.Vaccines (Basel). 2021 Dec 6;9(12):1438. doi: 10.3390/vaccines9121438. Vaccines (Basel). 2021. PMID: 34960184 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical